Skip to main content

Table 1 Comparison of pSS and non-pSS patients

From: Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjögren’s syndrome

  Overall pSS No pSS P value
n = 181 n = 77 n = 104
Age (years, mean ± SD) 56.1 ± 13.0 56.3 ± 13.5 55.9 ± 12.7 0.89
Symptom duration (years, mean ± SD) 6.4 ± 6.9 7.0 ± 7.6 6.0 ± 6.3 0.48
Female, n (%) 167 (92.2) 70 (90.9) 97 (93.3) 0.56
Xerophthalmia, n (%) 156 (86.2) 70 (90.9) 86 (82.7) 0.11
Xerostomia, n (%) 166 (91.7) 73 (94.8) 93 (89.4) 0.19
Abnormal Schirmer’s test, n (%) 76 (42.0) 44 (57.1) 32 (30.8) <0.001
Decreased salivary flow, n (%) 80 (44.2) 48 (62.3) 32 (30.8) <0.001
Abnormal salivary gland biopsy, n (%) 75 (41.4) 62 (80.5) 13 (12.5) <0.001
Anti-SSA or -SSB positivity, n (%) 47 (26.0) 47 (61.0) 0 (0.0) <0.001
AECG criteria, n (%) 67 (37.0) 64 (83.1) 3 (2.9) <0.001
Anti-SSA positivity, n (%) 47 (26.0) 47 (61.0) 0 (0.0) <0.001
Anti-SSB positivity, n (%) 25 (13.8) 25 (32.5) 0 (0.0) <0.001
ANA ≥1:320, n (%) 105 (58.0) 62 (80.5) 43 (41.3) <0.001
ANA ≥1:640, n (%) 73 (40.3) 54 (70.1) 19 (18.3) <0.001
IgM-RF positivity, n (%) 56 (30.9) 35 (45.5) 21 (20.2) <0.001
IgA-RF positivity, n (%) 37 (20.4) 32 (41.6) 5 (4.8) <0.001
Gammaglobulins ≥14 g/L, n (%) 44 (24.3) 36 (46.8) 8 (7.7) <0.001
IgG ≥14 g/L, n (%) 47 (26.0) 38 (49.4) 9 (8.7) <0.001
B-cell ratio ≥5, n (%) 59 (32.6) 41 (53.2) 18 (17.3) <0.001
ANA ≥1:320 + IgM-RF, n (%) 39 (21.5) 32 (41.6) 7 (6.7) <0.001
ACR criteria serologic item, n (%) 56 (30.9) 49 (63.6) 7 (6.7) <0.001
  1. pSS, primary Sjögren’s syndrome; AECG, American-European Consensus Group; ANA, antinuclear antibodies; Ig, immunoglobulin; RF, rheumatoid factor; ACR criteria serologic item: (anti-SSA/B or (ANA ≥1:320 + IgM-RF)). Xerophthalmia and xerostomia referred to subjective complaints by the patients. Schirmer’s test was considered abnormal if ≤5 mm/5 min and unstimulated salivary flow if ≤0.1 mL/min. Salivary gland biopsies were graded according to Chisholm and Mason. Mann–Whitney and chi-square tests were used as appropriate to compare pSS and non-pSS patients. P <0.05 was considered significant.